Sangamo Therapeutics Receives Nasdaq Delisting Notice: Trading to Move to OTCQB Venture Market

Key Points for Investors:

• Nasdaq Delisting: Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has received a formal notification from The Nasdaq Stock Market LLC regarding the delisting of its common stock.
• Failure to Meet Minimum Bid Price: The company’s common stock failed to maintain a minimum closing bid price of \$1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• Trading Suspension Date: Trading of SGMO shares on Nasdaq Capital Market will be suspended at the open of trading on May 5, 2026.
• Transition to OTCQB: Sangamo’s common stock has received approval to be quoted on the OTCQB Venture Market (an over-the-counter market), also starting May 5, 2026, under the same ticker symbol “SGMO”.
• Appeal Process: The company plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. A timely request will stay the delisting but will not stay the Nasdaq trading suspension. Shares will remain suspended on Nasdaq unless the Panel reinstates trading.

Detailed Report

Sangamo Therapeutics, Inc. announced that it has received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Staff”) on April 28, 2026, informing the company of its determination to delist Sangamo’s common stock due to continued non-compliance with the minimum bid price requirement. The company’s common stock, trading under the symbol SGMO, has traded below \$1.00 per share for 30 consecutive business days, breaching Nasdaq’s continued listing standards.

The company was initially notified of this deficiency on April 30, 2025, and was given until October 27, 2025, to regain compliance. As Sangamo did not meet the requirement by that date, it was granted an additional 180-day extension, until April 27, 2026. As of the notice on April 28, 2026, Sangamo had still not regained compliance, resulting in the Staff’s decision to move forward with delisting procedures.

The Delisting Notice further stated that, as of the open of trading on May 5, 2026, trading in Sangamo’s common stock will be suspended on the Nasdaq Capital Market. Importantly, Sangamo has already secured approval for its shares to be quoted on the OTCQB Venture Market, and trading is expected to begin there under the same symbol (“SGMO”) on May 5, 2026. This ensures that existing and prospective investors will still have access to a public trading venue for Sangamo shares, albeit one with typically lower liquidity and visibility than Nasdaq.

Sangamo intends to request a hearing before a Nasdaq Hearings Panel, as per the procedures outlined in the Nasdaq Listing Rule 5800 Series, to appeal the delisting determination. While a timely request for such a hearing will stay the delisting, it will not prevent the suspension of trading on Nasdaq. The company’s shares will only resume trading on Nasdaq if the Panel overturns the Staff’s decision.

Potential Impact on Shareholders and Share Price

• Trading Venue Change: Moving from Nasdaq to OTCQB generally results in decreased liquidity, lower analyst coverage, and may limit the ability of certain institutional investors to hold or acquire the stock. This can lead to increased volatility and possibly downward pressure on the share price.
• Perception of Financial Health: Failure to maintain listing standards can be viewed negatively by the market and may affect investor confidence in the company’s financial stability and future prospects.
• Future Corporate Actions: While the company is appealing the delisting, there is no guarantee that trading will resume on Nasdaq. Shareholders should monitor further announcements regarding the outcome of the hearing and any strategic actions Sangamo may take to regain compliance.

Forward-Looking Statements

The company cautioned investors that this disclosure contains forward-looking statements regarding its expectations for trading on the OTCQB, the appeal process, and the timing of these events. Actual results may differ due to risks and uncertainties, including those described in the “Risk Factors” section of Sangamo’s most recent filings with the SEC.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. All statements herein are based on publicly available filings and are subject to change based on future developments and regulatory actions.

View SANGAMO THERAPEUTICS, INC Historical chart here